journal article·2023-07Open access

Design and characterization of lipid nanocarriers for oral delivery of immunotherapeutic peptides

Xiomara Calderón‐Colón, Yichuan Zhang, Olivia Tiburzi, Jialu Wang, Shenda Hou, Giorgio Raimondi, Julia Patrone

Abstract

Abstract The use of therapeutic proteins and peptides is of great interest for the treatment of many diseases, and advances in nanotechnology offer a path toward their stable delivery via preferred routes of administration. In this study, we sought to design and formulate a nanostructured lipid carrier (NLC) containing a nominal antigen (insulin peptide) for oral delivery. We utilized the design of experiments (DOE) statistical method to determine the dependencies of formulation variables on physicochemical particle characteristics including particle size, polydispersity (PDI), melting point, and latent heat of melting. The particles were determined to be non‐toxic in vitro , readily taken up by primary immune cells, and found to accumulate in regional lymph nodes following oral administration. We believe that this platform technology could be broadly useful for the treatment of autoimmune diseases by supporting the development of oral delivery‐based antigen specific immunotherapies.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Advanced Drug Delivery Systems · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Johns Hopkins Applied Physics Laboratory Laurel Maryland USA

Department of Plastic & Reconstructive Surgery Johns Hopkins University School of Medicine Baltimore Maryland USA

References (47)

Show source-provided references
1. 10.1002/eji.20174705910.1002/eji.201747059 ↗
2. 10.1016/j.ejpb.2017.03.01510.1016/j.ejpb.2017.03.015 ↗
3. 10.1007/s12272-020-01219-010.1007/s12272-020-01219-0 ↗
4. 10.1002/adhm.20200016410.1002/adhm.202000164 ↗
5. 10.1021/acs.jmedchem.7b0031810.1021/acs.jmedchem.7b00318 ↗
6. 10.1007/s40199-019-00316-w10.1007/s40199-019-00316-w ↗
7. 10.3109/10717544.2013.81961110.3109/10717544.2013.819611 ↗
8. 10.1016/j.ijpharm.2018.02.03810.1016/j.ijpharm.2018.02.038 ↗
9. 10.1016/j.addr.2020.06.00310.1016/j.addr.2020.06.003 ↗
10. 10.1016/j.jconrel.2012.01.04310.1016/j.jconrel.2012.01.043 ↗
11. 10.1016/j.addr.2003.12.00210.1016/j.addr.2003.12.002 ↗
12. Advanced drug delivery to the lymphatic system: lipid‐based nanoformulations
13. 10.1016/j.ijpharm.2013.03.03410.1016/j.ijpharm.2013.03.034 ↗
14. 10.1016/j.ijpharm.2013.03.03610.1016/j.ijpharm.2013.03.036 ↗
15. 10.3892/ijmm.2012.108610.3892/ijmm.2012.1086 ↗
16. 10.1038/nrd460810.1038/nrd4608 ↗
17. 10.3390/molecules2505116110.3390/molecules25051161 ↗
18. 10.1016/j.jconrel.2016.07.05010.1016/j.jconrel.2016.07.050 ↗
19. 10.1016/j.nano.2018.10.00110.1016/j.nano.2018.10.001 ↗
20. 10.1038/s41587-019-0015-410.1038/s41587-019-0015-4 ↗
21. 10.1016/j.coi.2021.03.01910.1016/j.coi.2021.03.019 ↗
22. 10.1016/j.addr.2018.12.00310.1016/j.addr.2018.12.003 ↗
23. 10.1056/NEJMra191110910.1056/NEJMra1911109 ↗
24. 10.1016/S0939-6411(03)00067-510.1016/S0939-6411(03)00067-5 ↗
25. 10.1016/j.ijpharm.2006.08.00710.1016/j.ijpharm.2006.08.007 ↗
26. 10.1006/jaut.1994.106610.1006/jaut.1994.1066 ↗
27. 10.1084/jem.2011057410.1084/jem.20110574 ↗
28. 10.3791/5310210.3791/53102 ↗
29. 10.1021/acs.nanolett.1c0250310.1021/acs.nanolett.1c02503 ↗
30. 10.1021/acs.nanolett.5b0352810.1021/acs.nanolett.5b03528 ↗
31. Hydrophobic ion pairing of an insulin‐sodium deoxycholate complex for oral delivery of insulin
32. 10.1016/j.cis.2003.10.02310.1016/j.cis.2003.10.023 ↗
33. 10.1021/la001362n10.1021/la001362n ↗
34. 10.4049/jimmunol.090093610.4049/jimmunol.0900936 ↗
35. 10.3389/fimmu.2018.0156510.3389/fimmu.2018.01565 ↗
36. 10.1080/17425247.2017.126632910.1080/17425247.2017.1266329 ↗
37. AttamaA MomohMA BuildersPF.Lipid nanoparticulate drug delivery systems: a revolution in dosage form design and development;2012.
38. 10.2337/db11-067110.2337/db11-0671 ↗
39. 10.1371/journal.pone.011224210.1371/journal.pone.0112242 ↗
40. 10.3390/pharmaceutics1112067910.3390/pharmaceutics11120679 ↗
41. 10.2147/DDDT.S10439510.2147/DDDT.S104395 ↗
42. 10.2174/156720181666618112017013710.2174/1567201816666181120170137 ↗
43. 10.1002/wnan.4810.1002/wnan.48 ↗
44. 10.1038/s41578-019-0110-710.1038/s41578-019-0110-7 ↗
45. 10.1016/j.apsb.2021.04.00110.1016/j.apsb.2021.04.001 ↗
46. 10.1002/eji.20124239410.1002/eji.201242394 ↗
47. 10.1073/pnas.150296711210.1073/pnas.1502967112 ↗